-
Signature
-
/s/ Douglas Barry, Attorney-in-Fact
-
Issuer symbol
-
KNSA
-
Transactions as of
-
10 Feb 2026
-
Net transactions value
-
-$82,684
-
Form type
-
4
-
Filing time
-
12 Feb 2026, 16:34:44 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Quart Barry D |
Director |
C/O KINIKSA PHARMACEUTICALS INT'L, PLC, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM |
/s/ Douglas Barry, Attorney-in-Fact |
12 Feb 2026 |
0001384243 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
KNSA |
Class A Ordinary Share |
Options Exercise |
$1,702 |
+110 |
+0.88% |
$15.47 |
12,656 |
10 Feb 2026 |
Direct |
F1 |
| transaction |
KNSA |
Class A Ordinary Share |
Sale |
$4,950 |
-110 |
-0.87% |
$45.00 |
12,546 |
10 Feb 2026 |
Direct |
F1 |
| transaction |
KNSA |
Class A Ordinary Share |
Options Exercise |
$41,614 |
+2,690 |
+21% |
$15.47 |
15,236 |
12 Feb 2026 |
Direct |
F1 |
| transaction |
KNSA |
Class A Ordinary Share |
Sale |
$121,050 |
-2,690 |
-18% |
$45.00 |
12,546 |
12 Feb 2026 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
KNSA |
Share Option |
Options Exercise |
$0 |
-110 |
-3.9% |
$0.000000 |
2,690 |
10 Feb 2026 |
Class A Ordinary Shares |
110 |
$15.47 |
Direct |
F1, F2 |
| transaction |
KNSA |
Share Option |
Options Exercise |
$0 |
-2,690 |
-100% |
$0.000000 |
0 |
12 Feb 2026 |
Class A Ordinary Shares |
2,690 |
$15.47 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: